Pharmacological inhibition of EZH2 disrupts the female germline epigenome

Lexie Prokopuk1,2, Kirsten Hogg1,2, Patrick S Western1,2

  • 11Centre for Reproductive Health, Hudson Institute of Medical Research, Clayton, Victoria 3168 Australia.

Clinical Epigenetics
|March 9, 2018
PubMed
Abstract

Insights

Cancer drugs targeting EZH2 (Enhancer of Zeste 2) significantly deplete a key epigenetic mark, H3K27me3, in mouse oocytes. This depletion is long-lasting and may impact offspring development.

Area of Science:

  • Reproductive biology
  • Epigenetics
  • Developmental biology

Background:

  • Epigenetic modifying complexes are targets for novel cancer therapies.
  • Drugs targeting these complexes may impact germline epigenetic programming.
  • Enhancer of Zeste 2 (EZH2) is crucial for establishing H3K27me3 during development.

Purpose of the Study:

  • To investigate the effects of EZH1/2 inhibition on H3K27me3 in mouse oocytes.
  • To determine if H3K27me3 levels recover after drug treatment.

Main Methods:

  • Treatment of adult female mice with tazemetostat, a clinically relevant EZH1/2 inhibitor.
  • Analysis of H3K27me3 levels in growing, primary, and fetal oocytes.
  • Assessment of H3K27me3 recovery post-inhibition.

Main Results:

  • Tazemetostat severely depleted H3K27me3 in growing oocytes.
  • H3K27me3 was also depleted in primary and fetal oocytes.
  • H3K27me3 failed to recover in oocytes after EZH1/2 inhibition.

Conclusions:

  • Drugs targeting EZH2 significantly impact the germline epigenome.
  • Oocyte-specific loss of EZH2 function suggests potential effects on offspring outcomes.
  • Further research is needed to understand the long-term consequences for reproductive health.

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.3K
Infertility in Females01:28

Infertility in Females

Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
4.9K
External Female Genitals01:15

External Female Genitals

The vulva encompasses the external structures of the female reproductive system. At the forefront is the monpubis, a cushion of fatty tissue atop the pubic bone. Once puberty sets in, this area typically grows hair. Extending from just behind the mons pubis are the labia majora (labia = 'lips'; majora = 'larger'), which are larger skin fs olds coated with hair. Nestled within are the labia minora (labia = 'lips'; minora = 'smaller'), which are thinner, more...
35.8K
Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
4.5K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K